New insights into combined immunotherapy for hepatocellular carcinoma associated with liver cirrhosis
Yufan Liu, Kexin Cong, Qiao Li, Dan Zhang, Jiyao Sheng · 2025
Read New insights into combined immunotherapy for hepatocellular carcinoma associated with liver cirrhosis by Yufan Liu, Kexin Cong, Qiao Li, Dan Zhang, Jiyao Sheng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12756107.txt.
Description
Yufan Liu and co-authors review why liver scarring blunts immune therapy for liver cancer and how combination plans might break through, in work from twenty twenty-five. Most liver cancers grow on cirrhotic livers, where chronic inflammation and immune failure build a suppressive neighborhood. Checkpoint drugs answer in only a minority of patients.
The review maps how cirrhosis rewires the liver's immune cells: dendritic cells, T cells, macrophages, and neutrophils shift in count, function, and metabolism. Each shift helps shield the tumor. Candidate targets and pairing strategies aim to correct those faults. The authors frame the cirrhotic microenvironment as the next frontier for raising response rates.
Catalog record
| CREATOR | Yufan Liu, Kexin Cong, Qiao Li, Dan Zhang, Jiyao Sheng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |